Introduction
Etiology of CMV Colitis
CMV colitis predominantly arises in individuals with compromised immune systems. This includes patients with conditions like acquired immunodeficiency syndrome (AIDS), recipients of organ transplants, those with hematological malignancies, individuals undergoing cancer therapy, and patients on prolonged corticosteroid therapy. However, it is critical to recognize that CMV colitis is not exclusive to immunocompromised populations and can also occur in immunocompetent individuals. In immunocompetent patients who develop CMV colitis, the median age is typically higher, around 68 years, and they often present with symptoms such as persistent diarrhea, abdominal pain, and hematochezia or melena. Interestingly, a subset of these patients, approximately 25%, experience spontaneous resolution of CMV colitis without requiring antiviral treatment, highlighting the variable clinical course of the infection in different patient groups.[1]
Research by Ko JH et al., through a case-control study, has identified several risk factors that predispose immunocompetent individuals to CMV colitis. These risk factors include pre-existing renal diseases, patients undergoing hemodialysis, neurological disorders, rheumatic diseases, admission to the intensive care unit (ICU), and exposure to antibiotics, antacids, corticosteroids, or red blood cell transfusions within the month preceding colitis diagnosis.[2] Further detailed analysis by these researchers pinpointed corticosteroid use and recent red blood cell transfusion as independent risk factors for CMV colitis even in immunocompetent individuals. Therefore, it is crucial to consider CMV colitis in the differential diagnosis not only for immunocompromised patients but also for immunocompetent individuals, especially elderly patients presenting with hematochezia who have underlying comorbidities, have been admitted to intensive care, or have received corticosteroids or blood transfusions. CMV colitis also shows a strong association with acute, severe ulcerative colitis, particularly in patients managed with high-dose corticosteroids.[3] Furthermore, CMV infection, encompassing CMV colitis, represents a significant clinical challenge in patients post-solid organ transplantation or allogeneic stem cell transplantation, necessitating vigilant monitoring and diagnostic strategies.
Epidemiology of CMV Colitis
The global prevalence of CMV, as determined by serological studies, is remarkably high, affecting approximately 70% of adults and reaching nearly 100% in impoverished communities and developing nations.[4] Within the context of severe acute colitis, the prevalence of CMV infection ranges considerably, from 21% to 34%.[5][6] CMV reactivation in patients suffering from severe ulcerative colitis is reported to occur with a prevalence between 4.5% and 16.6%, and can escalate to as high as 25% in patients who ultimately require colectomy due to severe colitis. In patients with severe corticosteroid-refractory ulcerative colitis, the CMV infection rate is substantial, ranging from 20% to 40%, particularly when diagnosis is based on antigenemia and histological examination of tissue biopsies.[7][8] These epidemiological figures underscore the significant clinical burden of CMV colitis, especially in vulnerable patient populations.
Pathophysiology of CMV Colitis
Primary CMV infection in individuals with intact immune systems is typically asymptomatic, and viral reactivation in these individuals is also usually without symptoms. However, in immunocompromised patients, CMV reactivation can lead to symptomatic disease in various organs, including the colon, resulting in CMV colitis. The body’s immune response to CMV infection includes the production of specific immunoglobulin (IgM) antibodies, which are elevated during acute or relapsing infections. IgM antibody levels generally decline over 3 to 6 months but may persist for up to 12 to 24 months, potentially influenced by concurrent immunosuppression. Immunoglobulin IgG antibodies appear within a week of IgM antibodies; the presence of CMV IgG antibodies signifies prior exposure and seropositivity.
The gastrointestinal tract, particularly the colon and esophagus, are frequent sites of CMV infection. The precise role of CMV in inflammatory bowel disease (IBD) remains a subject of ongoing debate. Key questions persist regarding whether CMV reactivation contributes to exacerbations of pre-existing IBD or if it is merely a consequence of the disease or its treatment, or even an incidental finding.[9][10] Beyond the inflammatory processes inherent in IBD, research indicates that immunosuppression induced by high-dose systemic corticosteroids is significantly associated with CMV colitis in patients with active ulcerative colitis. Furthermore, certain immunomodulators used in ulcerative colitis management, such as thiopurines and methotrexate, but notably not anti-tumor necrosis factor (TNF) agents, have been linked to CMV infection in ulcerative colitis patients.[11][12] Patients who have undergone allogeneic stem cell transplantation are also at elevated risk of CMV infection or reactivation. In these patients, it is crucial to differentiate between gastrointestinal graft-versus-host disease (GVHD) and CMV colitis, as CMV viremia alone can be misleading. Colonic mucosal biopsies and detailed histological examination are essential for accurate diagnosis in this context.[13]
Histopathological Diagnosis of CMV Colitis
Definitive diagnosis of CMV colitis hinges on histopathological examination of biopsy specimens obtained from the ulcer margins or base within the colon. Studies suggest that patients presenting with punched-out ulcers tend to exhibit a higher density of inclusion bodies on histological analysis.[14] Histopathology not only confirms CMV colitis but also aids in differentiating it from other forms of colitis, such as infectious colitis, ulcerative colitis, drug-induced colitis, and also from rectal carcinoma.[15] Colonic mucosal biopsies stained with hematoxylin and eosin (H&E) may reveal characteristic “owl eye” inclusions, which are highly specific for CMV. However, the sensitivity of H&E staining is limited when compared to immunohistochemistry (IHC). IHC is therefore considered the gold standard for the histopathological diagnosis of CMV colitis, providing enhanced sensitivity and specificity in identifying CMV in tissue samples.
Alt text: Microscopic view of CMV colitis, hematoxylin and eosin stain, revealing pathognomonic “owl’s eye” inclusions indicative of cytomegalovirus infection in colon tissue.
History and Physical Examination in CMV Colitis
CMV infection often proceeds asymptomatically in immunocompetent individuals. In contrast, immunocompromised patients may develop symptoms, although the clinical presentation of CMV colitis is generally non-specific. Presenting symptoms, when they occur, typically include diarrhea, abdominal pain, fever, malaise, rectal bleeding, and weight loss. Notably, hematochezia and diarrhea are the most frequently observed symptoms in patients with confirmed CMV colitis. These symptoms often mimic exacerbations of inflammatory bowel disease, making it challenging to distinguish between ulcerative colitis and CMV colitis based solely on clinical presentation.[16] Therefore, while history and physical examination are crucial, they are insufficient for definitive diagnosis and must be complemented by specific diagnostic evaluations.
Evaluation and Diagnosis of CMV Colitis
Diagnosing CMV colitis necessitates a combination of serologic testing and endoscopic biopsies to achieve confirmation.
Serologic Testing for CMV Colitis Diagnosis
CMV IgG Test: This test is valuable for determining prior exposure to CMV. However, it lacks diagnostic utility in the acute diagnosis of CMV colitis as it only indicates past infection, not active disease in the colon.
CMV IgM Test: This test can detect a recent primary systemic CMV infection or systemic reactivation. However, similar to the IgG test, it is not specific for CMV colitis and does not confirm CMV involvement in the colon.
CMV Antigenemia Assay: This assay may offer some utility in the early diagnosis of CMV colitis and potentially in predicting clinical outcomes. However, it is generally considered to have lower sensitivity for diagnosing CMV colitis compared to tissue-based methods.
Endoscopic Evaluation for CMV Colitis Diagnosis
Endoscopy plays a crucial role in the diagnostic pathway for CMV colitis. A significant endoscopic finding, observed in 70% to 80% of patients, is the presence of ulcerations with a distinctive, punched-out appearance within the colonic mucosa.[16][17] However, ulcer morphology can be variable, sometimes appearing irregular or cobblestone-like. In patients with graft-versus-host disease, an ulcer in the cecum that involves the ileocecal valve has been suggested as a more specific endoscopic indicator of CMV colitis.[18]
The definitive identification of CMV disease through tissue sections stained with H&E relies on the detection of CMV viral inclusions. These characteristic “owl eye” inclusions are highly specific for CMV. However, for enhanced diagnostic accuracy, CMV-specific immunohistochemistry (IHC) is considered the gold standard for identifying CMV in tissue biopsies.[19] Therefore, if H&E-stained tissue sections are negative, but clinical suspicion for CMV colitis remains high, particularly in at-risk patients, IHC staining and examination of tissue sections are strongly recommended to improve diagnostic sensitivity.
Real-time Polymerase Chain Reaction (PCR) CMV DNA Quantification
Real-time PCR for CMV DNA quantification can be utilized in conjunction with endoscopic findings to aid in diagnosis. However, it is important to note that PCR may yield false negative results, with studies indicating positivity in only about 50% of patients with biopsy-proven CMV colitis/enteritis.[13] Therefore, while PCR can be supportive, it should not be relied upon as the sole diagnostic modality.
CMV Culture for CMV Colitis Diagnosis
CMV culture is a diagnostic method with high sensitivity and specificity for CMV colitis. It is non-invasive and generally accessible in clinical laboratories. However, a significant limitation of CMV culture is the prolonged turnaround time for results. This delay can impede rapid diagnosis and timely initiation of treatment, particularly in vulnerable patient populations where prompt intervention is critical.[20]
Treatment and Management of CMV Colitis
The therapeutic approach to CMV colitis varies depending on the patient’s immune status and the severity of the disease. For the majority of immunocompetent patients with CMV colitis, antiviral medications may not be necessary. This is largely due to the potential side effects associated with antiviral drugs, such as ganciclovir, and the limited evidence suggesting that antiviral treatment significantly alters outcomes in this patient group. Side effects of ganciclovir include myelosuppression, hepatotoxicity, nephrotoxicity, and central nervous system disorders. However, antiviral treatment in immunocompetent patients might be considered in specific scenarios, such as in males over 55 years of age with severe disease and co-morbidities that further compromise the immune system, such as diabetes mellitus or chronic renal failure. In these selected cases, oral or intravenous ganciclovir is the antiviral drug of choice.[21]
In patients experiencing CMV reactivation, which is frequently observed in severe or corticosteroid-resistant inflammatory bowel disease, antiviral treatment is not routinely indicated. Often, in these cases, CMV is considered non-pathogenic, and antiviral therapy may not provide clinical benefit. However, specific indications for antiviral therapy in this context include:
- When CMV reactivation leads to the development of CMV colitis, and histological examination of mucosal tissue reveals high-grade CMV density, indicating active viral replication and tissue invasion.[22]
- Patients with low-grade CMV density who exhibit corticosteroid-refractory or corticosteroid-dependent disease, suggesting a potential contribution of CMV to the lack of treatment response.
- The presence of a large ulcer on endoscopy, which may indicate a more aggressive CMV infection requiring targeted antiviral intervention.
It is important to acknowledge that the existing literature on antiviral treatment for CMV colitis is limited, with some studies having methodological weaknesses. There is a need for more robust, large-scale randomized controlled trials to identify specific patient subgroups who are most likely to benefit from antiviral therapy and to determine if treatment improves outcomes such as colectomy rates and mortality. The concomitant use of anti-TNF therapy with antiviral therapy may be considered in ulcerative colitis patients with CMV reactivation, particularly in cases refractory to conventional treatment. Ganciclovir has demonstrated efficacy in both treating and preventing CMV disease in bone marrow transplant recipients.[23] Current research is actively exploring the identification of high-risk groups and the potential role of prophylactic antiviral therapy in preventing CMV colitis in these populations.[13]
Differential Diagnosis of CMV Colitis
The differential diagnosis for cytomegalovirus colitis is broad and encompasses several gastrointestinal conditions that can mimic its clinical presentation:
- Viral and bacterial gastroenteritis: These infectious conditions are common causes of diarrhea and abdominal pain and must be considered.
- Inflammatory bowel disease (IBD): Both ulcerative colitis and Crohn’s disease can present with similar symptoms, and CMV colitis can complicate IBD.
- Colorectal cancer: Neoplastic lesions in the colon can cause bleeding and changes in bowel habits.
- Toxic megacolon: A severe complication of colitis, including IBD and infectious colitis, characterized by colonic dilatation and systemic toxicity.
- Diverticulitis: Inflammation of colonic diverticula, which can cause abdominal pain and bleeding.
- Irritable bowel syndrome (IBS): While primarily a functional disorder, IBS can sometimes be considered in the differential diagnosis, although it typically lacks the inflammatory features of CMV colitis.
- Celiac disease: Malabsorption due to gluten sensitivity can cause diarrhea and weight loss.
- Graft-versus-host disease (GVHD): In transplant recipients, GVHD can affect the gastrointestinal tract and mimic CMV colitis.
Prognosis of CMV Colitis
The overall prognosis for CMV colitis is generally favorable, particularly with timely diagnosis and appropriate management. However, certain factors can influence prognosis and are associated with poorer outcomes and increased mortality risk. In immunocompetent patients, age is a significant prognostic factor, with patients older than 55 years exhibiting slightly higher mortality rates. Patients who require surgical intervention, such as colectomy, also tend to have a less favorable prognosis. Some studies suggest that male gender may be associated with increased mortality in CMV colitis. Early diagnosis and prompt treatment are critical in improving prognosis, especially in immunocompromised patients. For patients with CMV colitis reactivation in the setting of ulcerative colitis, the prognosis can be more guarded; however, timely and targeted treatment can significantly improve outcomes in this subgroup as well.[22]
Complications of CMV Colitis
Untreated or severe CMV colitis can lead to a range of complications, some of which are potentially life-threatening:[24][25]
- Chronic inflammation: Persistent CMV infection can perpetuate chronic inflammation in the colon, contributing to ongoing symptoms and tissue damage.
- Large bowel perforation: Severe CMV colitis can weaken the colonic wall, leading to perforation and peritonitis, a surgical emergency.
- Toxic megacolon: Similar to other forms of severe colitis, CMV colitis can precipitate toxic megacolon, requiring intensive medical management and potentially surgery.
- Pseudomembrane formation: Although more commonly associated with Clostridium difficile infection, pseudomembranes can occur in CMV colitis and exacerbate mucosal damage.
- Development of ischemic colitis: CMV colitis may compromise colonic blood flow, leading to ischemic colitis.
- Severe hemorrhage: Patients with CMV colitis complicating inflammatory bowel disease are at increased risk of severe colonic hemorrhage.
- Colon perforation: As mentioned earlier, perforation is a serious complication that can arise from severe CMV colitis, particularly in the context of IBD.
Deterrence and Patient Education for CMV Colitis
Primary prevention of CMV colitis is particularly crucial in immunocompromised patients, especially solid organ transplant recipients, to enhance clinical outcomes. Various strategies have been developed to prevent CMV infection in this vulnerable population, and ongoing research is exploring newer prophylactic therapies. However, definitive universal guidelines and thresholds for preventive strategies are still evolving and are often tailored based on local and individual risk factors.[26] Key recommendations from the Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation include:
- Strong recommendation for either universal prophylaxis or preemptive therapy to prevent CMV disease in all solid organ transplant recipients, reflecting the high risk in this group.
- Recommended prophylaxis duration of 3 to 6 months for kidney, liver, heart, and pancreas transplant recipients (strong recommendation), highlighting the need for extended protection during the highest risk period.
- Strong recommendation for using leukoreduced or CMV-seronegative blood products in the highest-risk seronegative recipients, emphasizing the importance of minimizing CMV exposure through blood transfusions.
- Recommendation against routine secondary prophylaxis after treatment of CMV infection (weak recommendation), suggesting that prolonged prophylaxis may not be universally necessary after successful treatment of active disease.
- Recommendation for the use of mTOR inhibitors in CMV seropositive kidney, liver, heart, and lung transplant recipients (moderate-strong recommendation), indicating a potential role for these immunosuppressants in reducing CMV risk in specific transplant settings.
Patient education is also vital. Patients, particularly those at risk, should be educated about the symptoms of CMV colitis, the importance of adhering to immunosuppression management plans, and the need for prompt reporting of any gastrointestinal symptoms to their healthcare providers.
Enhancing Healthcare Team Outcomes in CMV Colitis Management
Effective diagnosis and management of CMV colitis are complex and necessitate a collaborative, interprofessional team. This team typically includes gastroenterologists, internists, infectious disease specialists, pathologists, clinical pharmacists, specialized nurses, and, in transplant settings, transplant physicians. A coordinated approach is essential, especially for patients at high risk, to ensure early diagnosis and timely initiation of appropriate treatment. Specialty-trained nurses play a critical role in patient education, symptom monitoring, and ensuring adherence to clinical and serologic monitoring protocols, particularly post-transplantation, to facilitate early detection of potential infections. Clinical pharmacists contribute by optimizing medication management, monitoring drug levels, and identifying and preventing potential drug-drug interactions to minimize adverse outcomes from antiviral therapies and other medications. A well-integrated and collaborative interprofessional team approach is paramount to ensure that patients at highest risk of CMV colitis receive optimal prophylaxis, vigilant monitoring, and evidence-based treatment. This coordinated care model ultimately leads to improved clinical outcomes and enhanced quality of life for patients affected by CMV colitis.
Review Questions
(Note: Review questions are present in the original article but are not included in this rewritten version as per instructions)
References
1.Karigane D, Takaya S, Seki Y, Mastumoto Y, Onose A, Kosakai A, Sugaya N, Mori T. Cytomegalovirus enteritis in immunocompetent subjects: a case report and review of the literature. J Infect Chemother. 2014 May;20(5):325-9. [PubMed: 24751234]
2.Ko JH, Peck KR, Lee WJ, Lee JY, Cho SY, Ha YE, Kang CI, Chung DR, Kim YH, Lee NY, Kim KM, Song JH. Clinical presentation and risk factors for cytomegalovirus colitis in immunocompetent adult patients. Clin Infect Dis. 2015 Mar 15;60(6):e20-6. [PubMed: 25452594]
3.Lee HS, Park SH, Kim SH, Kim J, Choi J, Lee HJ, Kim WS, Lee JM, Kwak MS, Hwang SW, Yang DH, Kim KJ, Ye BD, Byeon JS, Myung SJ, Yoon YS, Yu CS, Kim JH, Yang SK. Risk Factors and Clinical Outcomes Associated with Cytomegalovirus Colitis in Patients with Acute Severe Ulcerative Colitis. Inflamm Bowel Dis. 2016 Apr;22(4):912-8. [PubMed: 26829410]
4.Banerjee D, Deb R, Dar L, Mirdha BR, Pati SK, Thareja S, Falodia S, Ahuja V. High frequency of parasitic and viral stool pathogens in patients with active ulcerative colitis: report from a tropical country. Scand J Gastroenterol. 2009;44(3):325-31. [PubMed: 19040190]
5.Wada Y, Matsui T, Matake H, Sakurai T, Yamamoto J, Kikuchi Y, Yorioka M, Tsuda S, Yao T, Yao S, Haraoka S, Iwashita A. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum. 2003 Oct;46(10 Suppl):S59-65. [PubMed: 14530660]
6.Criscuoli V, Casà A, Orlando A, Pecoraro G, Oliva L, Traina M, Rizzo A, Cottone M. Severe acute colitis associated with CMV: a prevalence study. Dig Liver Dis. 2004 Dec;36(12):818-20. [PubMed: 15646428]
7.Domènech E, Vega R, Ojanguren I, Hernández A, Garcia-Planella E, Bernal I, Rosinach M, Boix J, Cabré E, Gassull MA. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis. 2008 Oct;14(10):1373-9. [PubMed: 18452205]
8.Maconi G, Lombardini M, Furfaro F, Bezzio C, Zerbi P, Ardizzone S. Long-term outcome of inflammatory bowel diseases with cytomegalovirus colitis: effect of antiviral treatment. Eur J Gastroenterol Hepatol. 2014 Oct;26(10):1146-51. [PubMed: 25089547]
9.Park SC, Jeen YM, Jeen YT. Approach to cytomegalovirus infections in patients with ulcerative colitis. Korean J Intern Med. 2017 May;32(3):383-392. [PMC free article: PMC5432807] [PubMed: 28490715]
10.Papadakis KA, Tung JK, Binder SW, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol. 2001 Jul;96(7):2137-42. [PubMed: 11467645]
11.Shukla T, Singh S, Tandon P, McCurdy JD. Corticosteroids and Thiopurines, But Not Tumor Necrosis Factor Antagonists, are Associated With Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2017 May/Jun;51(5):394-401. [PubMed: 27875356]
12.McCurdy JD, Jones A, Enders FT, Killian JM, Loftus EV, Smyrk TC, Bruining DH. A model for identifying cytomegalovirus in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015 Jan;13(1):131-7; quiz e7. [PubMed: 24993369]
13.Bhutani D, Dyson G, Manasa R, Deol A, Ratanatharathorn V, Ayash L, Abidi M, Lum LG, Al-Kadhimi Z, Uberti JP. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2015 Jan;21(1):159-64. [PMC free article: PMC4283200] [PubMed: 25445637]
14.Yang H, Zhou W, Lv H, Wu D, Feng Y, Shu H, Jin M, Hu L, Wang Q, Wu D, Chen J, Qian J. The Association Between CMV Viremia or Endoscopic Features and Histopathological Characteristics of CMV Colitis in Patients with Underlying Ulcerative Colitis. Inflamm Bowel Dis. 2017 May;23(5):814-821. [PubMed: 28426459]
15.Chidlovskii E, Deroux A, Bernard S, Couturier P. Cytomegalovirus colitis mimicking rectal carcinoma in an immunocompetent elderly woman. BMJ Case Rep. 2016 May 10;2016 [PMC free article: PMC4885349] [PubMed: 27166009]
16.Levin A, Yaari S, Stoff R, Caplan O, Wolf DG, Israeli E. Diagnosis of Cytomegalovirus Infection during Exacerbation of Ulcerative Colitis. Digestion. 2017;96(3):142-148. [PubMed: 28848127]
17.Suzuki H, Kato J, Kuriyama M, Hiraoka S, Kuwaki K, Yamamoto K. Specific endoscopic features of ulcerative colitis complicated by cytomegalovirus infection. World J Gastroenterol. 2010 Mar 14;16(10):1245-51. [PMC free article: PMC2839178] [PubMed: 20222169]
18.Matsuda K, Ono S, Ishikawa M, Miyamoto S, Abiko S, Tsuda M, Yamamoto K, Kudo T, Shimizu Y, Hayase E, Hashimoto D, Teshima T, Matsuno Y, Sakamoto N. Cecum ulcer is a reliable endoscopic finding in cytomegalovirus colitis concomitant with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2018 May;97(5):877-883. [PubMed: 29340759]
19.Juric-Sekhar G, Upton MP, Swanson PE, Westerhoff M. Cytomegalovirus (CMV) in gastrointestinal mucosal biopsies: should a pathologist perform CMV immunohistochemistry if the clinician requests it? Hum Pathol. 2017 Feb;60:11-15. [PubMed: 27666768]
20.Landry ML, Ferguson D. Comparison of quantitative cytomegalovirus antigenemia assay with culture methods and correlation with clinical disease. J Clin Microbiol. 1993 Nov;31(11):2851-6. [PMC free article: PMC266143] [PubMed: 8263166]
21.Yerushalmy-Feler A, Padlipsky J, Cohen S. Diagnosis and Management of CMV Colitis. Curr Infect Dis Rep. 2019 Feb 15;21(2):5. [PubMed: 30771028]
22.Beswick L, Ye B, van Langenberg DR. Toward an Algorithm for the Diagnosis and Management of CMV in Patients with Colitis. Inflamm Bowel Dis. 2016 Dec;22(12):2966-2976. [PubMed: 27763950]
23.Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, Buhles WC, DeArmond B, Meyers JD. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991 Dec 05;325(23):1601-7. [PubMed: 1658652]
24.Barling DR, Tucker S, Varia H, Isaacs P. Large bowel perforation secondary to CMV colitis: an unusual primary presentation of HIV infection. BMJ Case Rep. 2016 Dec 21;2016 [PMC free article: PMC5237779] [PubMed: 28003231]
25.Hasegawa T, Aomatsu K, Nakamura M, Aomatsu N, Aomatsu K. Cytomegalovirus colitis followed by ischemic colitis in a non-immunocompromised adult: a case report. World J Gastroenterol. 2015 Mar 28;21(12):3750-4. [PMC free article: PMC4375603] [PubMed: 25834346]
26.Kotton CN. CMV: Prevention, Diagnosis and Therapy. Am J Transplant. 2013 Feb;13 Suppl 3:24-40; quiz 40. [PubMed: 23347212]
